Adamumab is a self injectable biological therapy drug that has been approved by the State Food and Drug Administration (CFDA) for two indications, namely rheumatoid arthritis and ankylosing spondylitis.
English name | Adalimumab |
Commonly used name | Adamtuzumab Shumeile (Adamtuzumab) |
English alias | Adalimumab D2E7 Humira Immunoglobulin G1, anti – (human tumor necrosis factor) (human monoclone D2E7 heavy chain), disable with human monoclone D2E7 light chain, dimer |
Molecular formula | C6428H9912N1694O1987S46 |
Molecular weight | 144190.3 |
Subfraction | 148,108 ±8Da |
Supplement | Mannitol 、
Citrate monohydratel 、
Sodium citratel 、
Sodium dihydrogen phosphate l 、dihydratel 、
Disodium hydrogen phosphate dihydratel 、
Sodium chloridel 、
Polysorbate 80l 、
Sodium hydroxidel 、
Water for injection
|